DrugPatentWatch Database Preview
Drugs in Development Information for GSK2982772
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for GSK2982772?
GSK2982772 is an investigational drug.
There have been 9 clinical trials for GSK2982772.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Autoimmune Diseases, Psoriasis, and Inflammatory Bowel Diseases. The leading clinical trial sponsors are GlaxoSmithKline, Clinical Unit at Cambridge (Addenbrooks), and Quotient Sciences.
There are six US patents protecting this investigational drug and one hundred and one international patents.
Summary for GSK2982772
| US Patents | 6 |
| International Patents | 101 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2016-11-01) |
| Vendors | 19 |
Recent Clinical Trials for GSK2982772
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants | GlaxoSmithKline | Phase 1 |
| A Study to Investigate the Pharmacokinetics of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 | Quotient Sciences | Phase 1 |
| A Study to Investigate the Pharmacokinetics of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 | GlaxoSmithKline | Phase 1 |
Clinical Trial Summary for GSK2982772
Top disease conditions for GSK2982772
Top clinical trial sponsors for GSK2982772
US Patents for GSK2982772
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GSK2982772 | Start Trial | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-- yl)-4H-1,2,4-triazole-3-carboxamide | GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) | Start Trial |
| GSK2982772 | Start Trial | Heterocyclic amides as kinase inhibitors | GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) | Start Trial |
| GSK2982772 | Start Trial | Heterocyclic amides as kinase inhibitors | GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GSK2982772
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GSK2982772 | Australia | 2016217496 | 2035-02-13 | Start Trial |
| GSK2982772 | Brazil | 112017017411 | 2035-02-13 | Start Trial |
| GSK2982772 | Canada | 2976172 | 2035-02-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
